Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Taysha Gene Therapies stock

Own Taysha Gene Therapies stock in just a few minutes.

Taysha Gene Therapies, Inc is a biotechnology business based in the US. Taysha Gene Therapies shares (TSHA) are listed on the NASDAQ and all prices are listed in US Dollars. Taysha Gene Therapies employs 38 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Taysha Gene Therapies

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TSHA – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Taysha Gene Therapies share price

Use our graph to track the performance of TSHA stocks over time.

Taysha Gene Therapies shares at a glance

Information last updated 2021-04-23.
52-week range$18.16 - $33.35
50-day moving average $23.35
200-day moving average $24.10
Wall St. target price$45.10
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Taysha Gene Therapies shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Taysha Gene Therapies stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Taysha Gene Therapies financials

Gross profit TTM $0
Return on assets TTM -20.76%
Return on equity TTM -47.79%
Profit margin 0%
Book value N/A
Market capitalisation $906.8 million

TTM: trailing 12 months

Shorting Taysha Gene Therapies shares

There are currently 1.4 million Taysha Gene Therapies shares held short by investors – that's known as Taysha Gene Therapies's "short interest". This figure is 7.5% up from 1.3 million last month.

There are a few different ways that this level of interest in shorting Taysha Gene Therapies shares can be evaluated.

Taysha Gene Therapies's "short interest ratio" (SIR)

Taysha Gene Therapies's "short interest ratio" (SIR) is the quantity of Taysha Gene Therapies shares currently shorted divided by the average quantity of Taysha Gene Therapies shares traded daily (recently around 76118.041511442). Taysha Gene Therapies's SIR currently stands at 18.79. In other words for every 100,000 Taysha Gene Therapies shares traded daily on the market, roughly 18790 shares are currently held short.

To gain some more context, you can compare Taysha Gene Therapies's short interest ratio against those of similar companies.

However Taysha Gene Therapies's short interest can also be evaluated against the total number of Taysha Gene Therapies shares, or, against the total number of tradable Taysha Gene Therapies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Taysha Gene Therapies's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Taysha Gene Therapies shares in existence, roughly 40 shares are currently held short) or 0.0875% of the tradable shares (for every 100,000 tradable Taysha Gene Therapies shares, roughly 88 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Taysha Gene Therapies.

Find out more about how you can short Taysha Gene Therapies stock.

Taysha Gene Therapies share dividends

We're not expecting Taysha Gene Therapies to pay a dividend over the next 12 months.

Taysha Gene Therapies overview

Taysha Gene Therapies, Inc. , a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-101 for the treatment of GM2 gangliosidosis; TSHA-118 for the treatment of CLN1 disease; and TSHA-102 for the treatment of Rett syndrome. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments; and collaboration with Yale University to advance mini-gene payloads for an AAV gene therapy for the treatment of neurodevelopmental disorders. The company was incorporated in 2019 and is based in Dallas, Texas. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site